Pharmacovigilance and Patient Safety. Dr M. Roy Jobson Chairperson: Pharmacovigilance Committee of the MCC

Similar documents
Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS

The Need for National Pharmacovigilance Program

The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective

Risk Management Plan Guidance

Regulatory Aspects of Pharmacovigilance

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

Furthermore, the level of information and the subsequent assessment will vary on a case by case basis.

MEDICINES CONTROL COUNCIL

KLH-21 version 7 With effect from the date of issue (effective date 20th July 2018), this guideline supersedes guideline KLH-21, version 6.

PHARMACOVIGILANCE OF VETERINARY MEDICINAL PRODUCTS: MANAGEMENT OF ADVERSE EVENT REPORTS (AERS)

Pharmacovigilance Methods. The Spectrum of PV

Doc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021

CBA Workshop Series -3 Drug Safety (Pharmacovigilance) and Big Data. Larry Liu TCONNEX Inc.

Pharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri

MEDICINES CONTROL COUNCIL

GUIDANCE FOR INDUSTRY Clinical Safety Data Management Definitions and Standards for Expedited Reporting ICH Topic E2A

Contact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

Guidelines for Detecting & Reporting Adverse Drug Reactions

Quality check of spontaneous adverse drug reaction reporting forms of different countries y

PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR RECALL OF MEDICINES AND HEALTH PRODUCTS IN MALAWI

G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products.

VOLUME 9 - PHARMACOVIGILANCE. Medicinal Products for Human and Veterinary Use

Pharmacovigilance Practice in Pharmaceutical Industry. From Adverse Event Collection Risk Management

Belgian Centre for Pharmacotherapeutic Information

Health Canada s NHP Vigilance Activities

Pharmacovigilance System in Russia and the EAEU

Pharmacovigilance in Asia: The China Perspectives. Disclaimer

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

GUIDELINES FOR REGISTRATION OF MEDICINES IN THE GAMBIA

Global Issue & Regulatory Control of Pharmacovigilance System: A Standard Operating Procedure for a New Develop Organization

harmacovigilance A wake up for

Pharmacovigilance Playbook (Part 1 of 2)

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

PHARMACOVIGILANCE IN AND EMERGING MARKETS: AN INDUSTRY PERSPECTIVE. Shashidhar Swamy (Head, Pharmacovigilance) Wockhardt limited, Mumbai

Guidance for Adverse Event Report from çachieving Guidance in Clinical Trial Safety Information among Stakeholderé Forum for Ethical Review Committee

Guideline on good pharmacovigilance practices (GVP)

REPORT ON MONITORING OF ADVERSE DRUG REACTIONS DUE TO ANTIMALARIAL USE IN TANZANIA

Saudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority

RESEARCH DURING PUBLIC HEALTH EMERGENCIES- ETHICAL ISSUES

Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety

Joint Research Office of Doncaster & Bassetlaw

378/2007 Coll. ACT of 6 December 2007 on Pharmaceuticals and on Amendments to Some Related Acts (the Act on Pharmaceuticals)

Proposed Regulatory Requirments National Health Act, Republic of South Africa CEASA Breakfast Meeting

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA Head of Unit

Template protocol for Investigational Medicinal product(imp) <Trial Acronym> <Full Protocol Title> <Version Number and Date>

MEDICINES CONTROL COUNCIL

2 Pharmacovigilance. 2.1 Fundamentals of Pharmacovigilance

Medicines Safety in WHO: promoting best practices in Pharmacovigilance. Dr Shanthi Pal Medicines Safety Programme Manager WHO (HQ)

OFFICE FOR RESEACH PROCEDURE. Sponsor Responsibilities in Investigator Initiated Studies

E2B, Safety databases & Eudravigilance

Pharmacovigilance Approach to Challenges with Use of Medicines. Oksana Lebega USAID SIAPS project Antalya, Turkey December 10-13, 2013

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015

Tanzania Food, Drugs And Cosmetics (Clinical Trials Control) THE TANZANIA FOOD, DRUGS AND COSMETICS ACT ARRANGEMENT OF REGULATIONS

Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration

The EU Risk Management Plan - a tool to address the uncertainties at the time of approval, and manage the risks of medicines

Health Products and Food Branch Inspectorate

Regulation of Cell and Gene Therapy Products in Canada

Adverse Event Reporting: During the Study

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

Legislation, Transition and Implementation Medicines Control Council & SA Health Products Regulatory Authority. SAAPI Conference April 2016

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a

EUROPEAN PHARMACEUTICAL MARKET RESEARCH ASSOCIATION (EphMRA) RESPONSE TO

Recent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility

Guideline on good pharmacovigilance practices (GVP)

Wissenswertes aus dem Bereich PHV

MPharm programme in Pharmacovigilance and Pharmacoepidemiology

Pharmacovigilance. An agency of the European Union

EphMRA Adverse Event Reporting Guidelines 2016

Adverse Event Reporting

SERIOUS ADVERSE EVENTS

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework

Recording, Managing and Reporting Adverse Events in the UK

Surveillance Part 2. Marcia A. Testa, MPH, PhD Harvard School of Public Health

PHARMACEUTICALS AND INTELLECTUAL PROPERTY TRAINING SEMINAR. Medicines: from discovery to patient

GUIDELINES ON THE IMPORT AND EXPORT OF REGISTERED MEDICINES

Nuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards

8 th Kitasato- Harvard Symposium

GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS

RESEARCH ETHICS BOARD GUIDELINES SUBMISSION OF RESEARCH PROJECTS

Guidelines for application for Registration of Medicinal Products 2006(DRA)

Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products (Therapeutic Products Fees Ordinance)

ENCePP Plenary: New Pharmacovigilance legislation

Pharmacovigilance for biotherapeutics: Partnering for patient safety

RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS

Comments from: 1. General comments

MEDICINES CONTROL COUNCIL

Regulatory system strengthening

Kingdom of Swaziland Ministry of Health. Guidelines on Import Procedures for Medicines

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives

CTFG 10 September 2010

Medical Device Regulatory Framework

F.No /13-DC (Pt-13A ) Office of Drugs Controller General (India) New Drugs Division

Re: Docket No. FDA 2005-D-0339: Draft Guidance on Drug Safety Information FDA's Communication to the Public

Evolve or die: the urgent need to streamline randomized trials

OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20

International Medication Safety Network. Links with Pharmacovigilance Centres Analysis of Data in Canada

GUIDELINES and FORMS TABLE OF CONTENTS

Practising Safety THE ROLE OF PHARMACOVIGILANCE IN PHARMACOECONOMICS

Transcription:

Pharmacovigilance and Patient Safety Dr M. Roy Jobson Chairperson: Pharmacovigilance Committee of the MCC

Outline Pharmacovigilance The South African Medicines Control Council (MCC) The National Adverse Drug Event Monitoring Centre (Clinical Trials) The process and Patient Safety Media Conclusion

Pharmacovigilance Pharmacovigilance is the science and activities relating to the: detection assessment understanding and prevention of adverse effects or any other possible drug-related problems

Are drugs safer today? (1) Lembit Rägo (WHO) During 1960-1999 there were 121 safety related withdrawals worldwide Market life was known for 87 of those Market life less than 2 years 31% Market life less than 5 years 50% Fung et al. Drug Information Journal, 2001; 35:293-317 During 1972-1994, 583 new active substances were approved Of these 59 were withdrawn later During 1990-2001 in UK 24 drugs were withdrawn due to safety reasons

Are drugs safer today? (2) Lembit Rägo (WHO) In England and Wales the number of deaths related to ADRs has increased during last 10 years Study of 3,277 Coroner s Inquests in one UK district showed during 1986-1991 10 deaths due to prescribing errors and 36 due to ADRs These 46 deaths made approximately 1 in 2000 Ferner et al. J R Soc Med, 1994;87:145-148 A meta-analysis of 39 prospective studies in USA ADRs between fourth and sixth leading cause of death in USA; fatality rate as a result of ADRs was estimated 0.32% among hospitalised patients The annual cost of ADR related hospital costs 1.6-4 billion US $ Lazarou et al. JAMA, 1998;279:1200-1205

MEDICINES AND RELATED SUBSTANCES CONTROL ACT 101 OF 1965 Regulation 1: Definitions adverse drug reaction means a response in human or animal to a medicine which is harmful and unintended and which occurs at any dosage and can also result from lack of efficacy of a medicine, off-label use of a medicine, overdose, misuse or abuse of a medicine.

The MCC Statutory Council 24 members appointed by Minister of Health Act 101 of 1965 last amendment May 2003 to make MCC a juristic person

MEDICINES AND RELATED SUBSTANCES CONTROL ACT 101 OF 1965 Section 1 In determining whether or not the registration or availability of a medicine is in the public interest, regard shall be had only to the safety, quality and therapeutic efficacy thereof in relation to its effect on the health of man or any animal, as the case may be.

Definition of a medicine A medicine means any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in -- a) the diagnosis, treatment, mitigation, or prevention of disease, abnormal physical or mental state or the symptoms thereof in man; or b) restoring, correcting or modifying any somatic or psychic or organic function in man. and also includes veterinary medicines.

STRUCTURE & PROCESS P&A Biologicals Medicines Control Council Compl. Med Clinical Trials CLINICAL Pharmacovigilance Committee Scheduling Com Veterinary Com NATIONAL PHARMACOVIGILANCE PROGRAMME (MRA -- Pretoria) MEDUNSA PV Centre NADEMC (National Centre) Cape Town Bloemfontein PV Centre ONDERSTEPOORT Veterinary unit

NADEMC The National Adverse Drug Event Monitoring Centre created in 1987 It is a WHO collaborating centre sends reports to the Uppsala Monitoring Centre part of(?) Quality Assurance and Safety: Medicines Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals Cluster Main conduit for spontaneous reporting of adverse drug reactions in South Africa (yellow form) [Patient reporting?] Based at UCT Interacts with Pharmaceutical Industry Reports to Pharmacovigilance Committee of MCC

South African issue? Adverse drug reactions are a sign that the medicine is working medicines are meant to make you feel bad A rash interpreted to be a sign of the disease coming out (logical!) Medicines a necessary part of life like food, air, water (e.g. vaseline???) Substitute one belief system for others: natural medicines are 100% safe and gentle ; we must sterilise our environments

Annual ADR Reporting Rate: South Number of Reports 1000 800 600 Africa 400 200 Manufacturer Direct 0 1987 1990 1993 1996 1999 2002 Year Source: National Adverse Drug Event Monitoring Centre, 2003

Signals A signal refers to reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information. Denominator unknown, so clinical trials / focused surveillance carried out

Clinical Trials Safety elements built into study design Pre-specified definitions of serious adverse events (SAEs) and adverse events (AEs) Blinding is a problem in terms of attribution Interim Analyses (independent DSMB) Can be very powerful e.g. worldwide withdrawal of rofecoxib

Patient Safety Adverse drug reactions reported, collated, international picture (vigimed/other), (interaction with industry), presented to pharmacovigilance committee, may consult Clinical Committee i.t.o risk-benefit profile, recommendation to Council Dear Health Professional Letter (DDL) Medicines Safety Alert (DA) Council can: instruct withdrawal of a medicine from market cancel registration of a medicine

Media Sensational items (compare to cars ) ARVs are poison [toxicity vs benefit The drugs are toxic but the disease is toxicer ] Business/profit driven misleading advertising ASA (refers to MRA!) Work with sound bites and headlines Talk shows barely scratch surface of issues (often just a vehicle for venting)

Conclusion Patient awareness of ADRs increasing but no concomitant communication / reporting to their health professionals? Health professionals not trained in recognising (and reporting) ADRs challenge for our academics (esp. paediatrics and dermatology) ART requires sharp learning curve for all i.t.o. management of ADRs Pharmacovigilance (detect, assess, understand, prevent ADRs + ) needs greater emphasis in improving patient safety